Barclays raised the firm’s price target on Legend Biotech to $93 from $92 and keeps an Overweight rating on the shares following Johnson & Johnson’s Q3 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>